AMEX:ELMD

Stock Analysis Report

Executive Summary

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation therapy in pulmonary care for patients of all ages in the United States and internationally.

Snowflake

Fundamentals

Flawless balance sheet and slightly overvalued.

Risks

  • Electromed is not covered by any analysts.

Similar Companies

Share Price & News

How has Electromed's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.9%

ELMD

0.7%

US Medical Equipment

-0.2%

US Market


1 Year Return

18.3%

ELMD

9.5%

US Medical Equipment

1.1%

US Market

ELMD outperformed the Medical Equipment industry which returned 9.5% over the past year.

ELMD outperformed the Market in United States of America which returned 1.1% over the past year.


Share holder returns

ELMDIndustryMarket
7 Day3.9%0.7%-0.2%
30 Day20.6%0.1%2.5%
90 Day16.6%2.5%1.6%
1 Year18.3%18.3%10.4%9.5%3.4%1.1%
3 Year40.1%40.1%69.3%64.1%45.2%35.8%
5 Year251.9%251.9%138.0%110.9%62.6%44.8%

Price Volatility Vs. Market

How volatile is Electromed's share price compared to the market and industry in the last 5 years?


Simply Wall St News

1 month ago | Simply Wall St

Can We See Significant Insider Ownership On The Electromed, Inc. (NYSEMKT:ELMD) Share Register?

Valuation

Is Electromed undervalued based on future cash flows and its price relative to the stock market?

26.95x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Electromed's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Electromed's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Electromed is good value based on earnings compared to the US Medical Equipment industry average.

Electromed is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Electromed, we can't assess if its growth is good value.


Price Based on Value of Assets

Electromed is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Electromed expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

10.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Electromed is high growth as no revenue estimate data is available.

Electromed's earnings are expected to grow by 10.2% yearly, however this is not considered high growth (20% yearly).

Unable to compare Electromed's revenue growth to the United States of America market average as no estimate data is available.

Electromed's earnings growth is positive but not above the United States of America market average.

Electromed's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Electromed will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Electromed performed over the past 5 years?

27.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Electromed has delivered over 20% year on year earnings growth in the past 5 years.

Electromed's 1-year earnings growth is less than its 5-year average (7.5% vs 27.1%)

Electromed's earnings growth has not exceeded the US Medical Equipment industry average in the past year (7.5% vs 28.2%).


Return on Equity

Electromed has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Electromed used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Electromed's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Electromed's financial position?


Financial Position Analysis

Electromed is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Electromed has no long term commitments.


Debt to Equity History and Analysis

Electromed has no debt.

Electromed has no debt compared to 5 years ago when it was 10.2%.

Electromed has no debt, it does not need to be covered by operating cash flow.

Electromed has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

High level of physical assets or inventory.

Electromed has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is Electromed's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Electromed's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Electromed's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Electromed has not reported any payouts.

Unable to verify if Electromed's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Electromed has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Electromed's salary, the management and board of directors tenure and is there insider trading?

4.3yrs

Average management tenure


CEO

Kathleen Skarvan (63yo)

6.8yrs

Tenure

US$724,148

Compensation

Ms. Kathleen S. Skarvan has been the Chief Executive Officer of Electromed, Inc. since December 1, 2012 and its President since August 28, 2015. Ms. Skarvan served as Vice President of Operations at OEM Fa ...


CEO Compensation Analysis

Kathleen's remuneration is higher than average for companies of similar size in United States of America.

Kathleen's compensation has increased by more than 20% in the past year whilst earnings grew less than 20%.


Management Age and Tenure

4.3yrs

Average Tenure

63yo

Average Age

The tenure for the Electromed management team is about average.


Board Age and Tenure

3.9yrs

Average Tenure

63yo

Average Age

The tenure for the Electromed board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$373,72413 Jun 19
Zenith Sterling Advisers Llc
EntityCompany
Shares70,500
Max PriceUS$5.56
BuyUS$57,14321 Feb 19
Stephen Craney
EntityIndividual
Role
Chairman of the Board
Chairman
Shares10,000
Max PriceUS$5.75

Ownership Breakdown


Management Team

  • Bill George (70yo)

    Secretary

    • Tenure: 0yrs
  • Kathleen Skarvan (63yo)

    CEO, President & Director

    • Tenure: 6.8yrs
    • Compensation: US$724.15k
  • Jeremy Brock (40yo)

    CFO, Principal Accounting Officer & Financial Controller

    • Tenure: 7.9yrs
    • Compensation: US$419.59k
  • Kathryn Thompson

    Vice President of Reimbursement

    • Tenure: 1.9yrs
  • Bud Reeves

    VP of Sales

    • Tenure: 0.4yrs

Board Members

  • Lee Jones (62yo)

    Director

    • Tenure: 5.1yrs
    • Compensation: US$24.44k
  • Greg Fluet (50yo)

    Director

    • Tenure: 0.08yrs
  • Kathleen Skarvan (63yo)

    CEO, President & Director

    • Tenure: 6.8yrs
    • Compensation: US$724.15k
  • William Eckles (44yo)

    Independent Director

    • Tenure: 8.2yrs
    • Compensation: US$26.54k
  • Stan Erickson (68yo)

    Vice Chairman of the Board

    • Tenure: 2.7yrs
    • Compensation: US$30.29k
  • George Winn (82yo)

    Director

    • Tenure: 14.7yrs
    • Compensation: US$22.69k
  • Steve Craney (75yo)

    Chairman

    • Tenure: 7.3yrs
    • Compensation: US$40.42k
  • Anne O'Donnell

    Member of Bronchiectasis Advisory Board

    • Tenure: 2.1yrs
  • Chad Marion

    Member of Bronchiectasis Advisory Board

    • Tenure: 2.1yrs
  • Peadar Noone

    Member of Bronchiectasis Advisory Board

    • Tenure: 2.1yrs

Company Information

Electromed, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Electromed, Inc.
  • Ticker: ELMD
  • Exchange: AMEX
  • Founded: 1992
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$53.937m
  • Shares outstanding: 8.44m
  • Website: https://www.smartvest.com

Number of Employees


Location

  • Electromed, Inc.
  • 500 Sixth Avenue NW
  • New Prague
  • Minnesota
  • 56071
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ELMDAMEX (NYSE MKT LLC)YesCommon StockUSUSDAug 2010

Biography

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation therapy in pulmonary care for patients of all ages ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 00:23
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.